- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This second HIVDR report provides an update on recent population levels of HIVDR covering the period 2014–2016. The report includes data from 16 nationally representative surveys from 14 countries estimating resistance in: adults initiating ART (PDR), children younger than 18 months newly diagnosed with HIV, and adults on ART (acquired HIV drug resistance or ADR).
To contextualize results from representative HIVDR surveys, the report is supported by systematic reviews of the published literature on PDR in adults, children and adolescents, and ADR in paediatric and adult populations.
With the 2016 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, WHO updated and launched new policy recommendations on the clinical and service delivery aspects of HIV treatment and care, and raised the bar to treat all PLHIV (Treat All). WHO has worked with countries to ensure uptake and implementation of these recommendations in support of the to the 90-90-90 targets.
Find HIV data on PMTCT, ANC, pregnant women, ART in Nepal.
Preventing and managing the emergence of HIVDR is a key component of a comprehensive and effective HIV response, and should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIVDR are implemented at the clinical, programme and policy levels to address the many drivers of HIVDR.
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents.
The 90-90-90 targets and the HIV testing and treatment cascade are two ways of looking at the same data. The targets were instrumental in galvanizing global action for HIV treatment access.
Keywords: HIV, PLHIV, targets, treatment, testing
This report provides in-depth technical discussions in areas that have direct implications to the containment of AMR as a development agenda. The report is organized in five chapters which served as the technical background documents for the Biregional Technical Consultation on AMR in Asia, 14-15 April 2016. More information from the meeting is available in the WHO Meeting Report: Biregional Technical Consultation on Antimicrobial Resistance in Asia. The meeting was the first time senior officials from the Ministry of Health and Ministry of Agriculture across Asia came together to tackle AMR.
Keywords: drug resistance, microbial, infection control
Competition law is an important policy tool that LMICs can use to protect consumer welfare and promote industrial and economic development. It aims to restrict unfair business practices, and promote quicker introduction and increased availability of health technologies. The issue brief highlights key aspects of using competition law to promote access to health technologies from UNDP’s landmark publication “Using Competition Law to Promote Access to Health Technologies: A guidebook for low- and middle-income countries.” The issue brief intends to be a resource for policymakers, national competition authorities, national procurement agencies, health authorities, civil society and other actors who have an interest in understanding the critical role of competition authorities in promoting access to health technologies.
Keywords: HIV, TB, LMICs, access, medicines, laws
In this Region, most mothers and children receive health services during pregnancy, delivery and in the months after birth. However, when services for HIV, hepatitis B and syphilis are planned and delivered through separate, uncoordinated, vertical programmes in the health system.
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach. This guidance document replaces the previous version published in 2013.
Keywords: antimicrobial use, analysis, reporting, data
This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.